Molecular Templates (MTEM) Competitors

Molecular Templates (NASDAQ:MTEM) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.

Does the media favor MTEM or AMGN?

In the previous week, Amgen had 48 more articles in the media than Molecular Templates. MarketBeat recorded 48 mentions for Amgen and 0 mentions for Molecular Templates. Amgen's average media sentiment score of 1.20 beat Molecular Templates' score of 0.00 indicating that Amgen is being referred to more favorably in the news media.

Company	Overall Sentiment
Molecular Templates	Neutral
Amgen	Positive

Do analysts rate MTEM or AMGN?

Amgen has a consensus target price of $309.22, indicating a potential upside of 13.72%. Given Amgen's stronger consensus rating and higher possible upside, analysts clearly believe Amgen is more favorable than Molecular Templates.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Templates	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Amgen	2 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.38

Does the MarketBeat Community favor MTEM or AMGN?

Amgen received 1217 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 71.71% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote.

Company	Underperform	Outperform
Molecular Templates	Outperform Votes 342 67.32%	Underperform Votes 166 32.68%
Amgen	Outperform Votes 1559 71.71%	Underperform Votes 615 28.29%

Which has better earnings & valuation, MTEM or AMGN?

Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Templates	$23.48M	0.00	-$8.12M	-$2.70	N/A
Amgen	$34.13B	4.28	$4.09B	$10.96	24.81

Do institutionals & insiders believe in MTEM or AMGN?

95.5% of Molecular Templates shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 13.9% of Molecular Templates shares are held by insiders. Comparatively, 0.8% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is MTEM or AMGN more profitable?

Amgen has a net margin of 12.24% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 176.32% beat Molecular Templates' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Templates	-61.35%	-260.50%	-46.90%
Amgen	12.24%	176.32%	11.71%

Which has more volatility and risk, MTEM or AMGN?

Molecular Templates has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Summary

Amgen beats Molecular Templates on 15 of the 18 factors compared between the two stocks.